This phase I trial studies the side effects and best dose of metformin and nelfinavir in combination with bortezomib in treating patients with multiple myeloma that has come back or does not respond to treatment. Metformin may stop the growth of tumor cells by disrupting the energy source within multiple myeloma cells. Nelfinavir and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving metformin, nelfinavir, and bortezomib may work better in treating patients with multiple myeloma.
SparkCures ID | 1001 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 9 Patients |
Treatments |
|
Trial Sponsors |
|
Trial Collaborators |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Measurable disease of multiple myeloma as defined by at least ONE of the following:
Serum monoclonal protein >= 0.5 g/dL
Exclusion Criteria:
The following populations should be excluded from study:
Any of the following recent prior anti-myeloma therapy:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers